Last reviewed 2026-06-02 · How we verify

pBCAR3-phosphopeptide

Craig L Slingluff, Jr · Phase 1 active Biologic ✓ Verified Jun 2026

pBCAR3-phosphopeptide is a Biologic drug developed by Craig L Slingluff, Jr. It is currently in Phase 1 development. Also known as: tet vaccine, polyICLC.

pBCAR3-phosphopeptide is being studied as a potential treatment for melanoma, as part of a multi-phosphopeptide vaccine combination. The vaccine, which includes pBCAR3-phosphopeptide, is being evaluated for its safety and immunogenicity in clinical trials.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	pBCAR3-phosphopeptide
Also known as	tet vaccine, polyICLC
Sponsor	Craig L Slingluff, Jr
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

pBCAR3-phosphopeptide CI brief — competitive landscape report
pBCAR3-phosphopeptide updates RSS · CI watch RSS
Craig L Slingluff, Jr portfolio CI

Frequently asked questions about pBCAR3-phosphopeptide

What is pBCAR3-phosphopeptide?

pBCAR3-phosphopeptide is a Biologic drug developed by Craig L Slingluff, Jr.

Who makes pBCAR3-phosphopeptide?

pBCAR3-phosphopeptide is developed by Craig L Slingluff, Jr (see full Craig L Slingluff, Jr pipeline at /company/craig-l-slingluff-jr).

Is pBCAR3-phosphopeptide also known as anything else?

pBCAR3-phosphopeptide is also known as tet vaccine, polyICLC.

What development phase is pBCAR3-phosphopeptide in?

pBCAR3-phosphopeptide is in Phase 1.

Manufacturer: Craig L Slingluff, Jr — full pipeline
Also known as: tet vaccine, polyICLC

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing